R&D cost to be reflected in insurance drug prices.

For the international competitiveness in the pharmaceutical industry to be enhanced and its leading role in the national economy of 21th century to be fostered, the KPMA raised several issues during an interview with President Kim on March 30 that the new drug R&D cost should be provisionally accounted when evaluating the new insurance drug price and that other financial support including lowe...